Spironolactone Does Not Cause Bone Marrow Depression
Spironolactone is not associated with bone marrow depression as a recognized adverse effect. The FDA drug label and major clinical guidelines do not list bone marrow suppression among spironolactone's adverse reactions 1.
Evidence from FDA Drug Labeling
The official FDA prescribing information for spironolactone lists hematologic adverse reactions as leukopenia (including agranulocytosis) and thrombocytopenia 1. These are distinct from bone marrow depression:
- Agranulocytosis is an extremely rare idiosyncratic reaction (approximately 6.2 cases per million persons annually) that appears to be a toxic effect rather than marrow suppression 2
- This occurs primarily in high-risk patients: elderly, hepatic/renal impairment, high doses, prolonged duration, or multiple concurrent medications 2
Recognized Adverse Effects
The well-documented adverse effects of spironolactone include 3, 4, 5:
- Hyperkalemia (most clinically significant - requires serial monitoring)
- Worsening renal function
- Gynecomastia (10% in men at 25 mg/day, up to 52% at ≥150 mg/day)
- Sexual dysfunction and menstrual irregularities
- Gastrointestinal symptoms
- Hypotension
Clinical Monitoring Requirements
Based on guideline recommendations, monitoring for spironolactone should focus on 3, 4:
- Serum potassium and renal function at baseline, 1 and 4 weeks after initiation, then at 1,2,3, and 6 months, followed by every 6 months
- Stop immediately if potassium >6.0 mmol/L or creatinine >310 mmol/L (3.5 mg/dL)
- No routine hematologic monitoring is recommended in the guidelines
Important Caveat
While one case report documents spironolactone-induced agranulocytosis with bone marrow biopsy evidence 2, this represents a rare idiosyncratic reaction rather than a class effect of bone marrow depression. The mechanism appears to be direct toxic effect rather than marrow suppression, and it resolved within 5 days of drug discontinuation.
In clinical practice, do not withhold spironolactone due to concerns about bone marrow depression, but monitor electrolytes and renal function vigilantly as per established protocols.